Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

The University of British Columbia

$33,000.00

Determining the Effects of Composition and Microfluidic Fabrication Parameters on Lipid Nanoparticle Structure and Function

FY 2024-25

Summary
RNA-based gene therapy has potential to cure most diseases but is limited because of challenges in delivering sufficient amounts of RNA to specific tissue or cells. For example, RNA-based gene therapy is used in the leading COVID-19 vaccines, including the one I helped develop, because it is easy to deliver RNA into the muscle. Self-amplifying RNA (saRNA) is a cutting-edge gene delivery platform; by encoding a replicase derived from an alphavirus genome, the RNA is able to replicate upon entry into the cell. The self-replicating properties result in a highly active form of RNA, and saRNA requires ~100-fold lower dose compared to messenger RNA. However, because saRNA is a large (~10,000 nt), anionic molecule, it requires a delivery system to promote cellular uptake. Due to their potency and scalability, lipid nanoparticles (LNPs) are the lead formulation for saRNA. However, current LNPs were optimized for smaller RNA (siRNA, mRNA), and are less suited to saRNA. While cellular activation by RNA is well-characterized, it is less clear how the physical characteristics of LNPs are detected by intracellular mechanisms of cells. We hypothesize that previously undefined nanoparticle characteristics, critical quality attributes (CQAs), can be tuned by the critical processing parameters (CPPs) to increase the functionality and batch-to-batch consistency of LNP formulations containing saRNA. The long-term objective of my research program is to gain a deeper understanding of the mechanisms that govern sensing of saRNA LNPs and to utilize biochemical design and processing parameters to enhance the immunological activity of saRNA formulations. Within the next five years, the short-term objectives are to understand how microfluidic processing parameters affect physical attributes of saRNA LNPs, and how these characteristics are sensed intracellularly: (1)We will use a high throughput Design of Experiments approach to optimize CPPs specifically for saRNA LNPs. (2)We will develop rigorous `fingerprinting' characterization methods and correlation with CPPs to create potent transfection agents for saRNA. (3)We will utilize saRNA LNPs with varying CQAs to understand the mechanisms underpinning intracellular sensing using single cell RNA sequencing and cytokine secretion profiles. These studies will establish the importance of the biological impact of RNA carriers, and not just the RNA itself, within the field of RNA delivery. As an interdisciplinary lab, the 21 HQP included in my overall research program will be trained in chemical engineering, biomaterials, and molecular biology techniques, and I will nurture a research group that promotes equity, diversity and inclusion of HQP at all skill levels and backgrounds. This research program will benefit Canada both by providing multifaceted training for the next generation of gene delivery scientists and developing technologies that directly translate to benefit the emerging and future industry in gene therapy.
Program
Discovery Grants Program - Individual
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2021-02931
Name nom
Blakney, Anna
Department département
Michael Smith Labs
Organization id
2
Institution établissement
The University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2021
Award amount
33000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Determining the Effects of Composition and Microfluidic Fabrication Parameters on Lipid Nanoparticle Structure and Function
Keywords
gene delivery; formulation science; rna; lipid nanoparticles; nanofabrication; microfluidics; particle characterization
Application summary
RNA-based gene therapy has potential to cure most diseases but is limited because of challenges in delivering sufficient amounts of RNA to specific tissue or cells. For example, RNA-based gene therapy is used in the leading COVID-19 vaccines, including the one I helped develop, because it is easy to deliver RNA into the muscle. Self-amplifying RNA (saRNA) is a cutting-edge gene delivery platform; by encoding a replicase derived from an alphavirus genome, the RNA is able to replicate upon entry into the cell. The self-replicating properties result in a highly active form of RNA, and saRNA requires ~100-fold lower dose compared to messenger RNA. However, because saRNA is a large (~10,000 nt), anionic molecule, it requires a delivery system to promote cellular uptake. Due to their potency and scalability, lipid nanoparticles (LNPs) are the lead formulation for saRNA. However, current LNPs were optimized for smaller RNA (siRNA, mRNA), and are less suited to saRNA. While cellular activation by RNA is well-characterized, it is less clear how the physical characteristics of LNPs are detected by intracellular mechanisms of cells. We hypothesize that previously undefined nanoparticle characteristics, critical quality attributes (CQAs), can be tuned by the critical processing parameters (CPPs) to increase the functionality and batch-to-batch consistency of LNP formulations containing saRNA. The long-term objective of my research program is to gain a deeper understanding of the mechanisms that govern sensing of saRNA LNPs and to utilize biochemical design and processing parameters to enhance the immunological activity of saRNA formulations. Within the next five years, the short-term objectives are to understand how microfluidic processing parameters affect physical attributes of saRNA LNPs, and how these characteristics are sensed intracellularly: (1)We will use a high throughput Design of Experiments approach to optimize CPPs specifically for saRNA LNPs. (2)We will develop rigorous `fingerprinting' characterization methods and correlation with CPPs to create potent transfection agents for saRNA. (3)We will utilize saRNA LNPs with varying CQAs to understand the mechanisms underpinning intracellular sensing using single cell RNA sequencing and cytokine secretion profiles. These studies will establish the importance of the biological impact of RNA carriers, and not just the RNA itself, within the field of RNA delivery. As an interdisciplinary lab, the 21 HQP included in my overall research program will be trained in chemical engineering, biomaterials, and molecular biology techniques, and I will nurture a research group that promotes equity, diversity and inclusion of HQP at all skill levels and backgrounds. This research program will benefit Canada both by providing multifaceted training for the next generation of gene delivery scientists and developing technologies that directly translate to benefit the emerging and future industry in gene therapy.